{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T07:55:35Z","timestamp":1718351735507},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Korea Health Industry Development Institute Research","award":["A121118"],"award-info":[{"award-number":["A121118"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.bbrc.2016.07.098","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T12:23:06Z","timestamp":1469535786000},"page":"553-558","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Glycyrrhizic acid prevents astrocyte death by neuromyelitis optica-specific IgG via inhibition of C1q binding"],"prefix":"10.1016","volume":"478","author":[{"given":"Ji-Sun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyoung","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boram","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heejaung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Duk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2016.07.098_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbrc.2016.07.098_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"N.M.O.D. International Panel for, International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2016.07.098_bib3","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"A\u00a0population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2016.07.098_bib4","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A\u00a0serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet (London, Engl.)"},{"key":"10.1016\/j.bbrc.2016.07.098_bib5","first-page":"99","article-title":"Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays","volume":"15","author":"Waters","year":"2008","journal-title":"Int. MS J. MS Forum."},{"key":"10.1016\/j.bbrc.2016.07.098_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.bbrc.2016.07.098_bib7","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A\u00a0serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet (London, Engl.)"},{"key":"10.1016\/j.bbrc.2016.07.098_bib8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in\u00a0vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbrc.2016.07.098_bib9","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2016.07.098_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbrc.2016.07.098_bib11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","article-title":"Ex\u00a0vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbrc.2016.07.098_bib12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-013-1128-3","article-title":"C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in\u00a0vitro and mouse models of neuromyelitis optica","volume":"125","author":"Phuan","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbrc.2016.07.098_bib13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbrc.2016.07.098_bib14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.apsb.2015.05.005","article-title":"The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb","volume":"5","author":"Wang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbrc.2016.07.098_bib15","doi-asserted-by":"crossref","first-page":"e89450","DOI":"10.1371\/journal.pone.0089450","article-title":"Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia\/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats","volume":"9","author":"Gong","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2016.07.098_bib16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2567.1997.00131.x","article-title":"Inhibition of human complement by beta-glycyrrhetinic acid","volume":"90","author":"Kroes","year":"1997","journal-title":"Immunology"},{"key":"10.1016\/j.bbrc.2016.07.098_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cmdc.201500546","article-title":"Screening, Synthesis, and in\u00a0vitro evaluation of vinyl sulfones as inhibitors of complement-dependent cytotoxicity in neuromyelitis optica","volume":"11","author":"Ju","year":"2016","journal-title":"Chemmedchem"},{"key":"10.1016\/j.bbrc.2016.07.098_bib18","first-page":"1","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.bbrc.2016.07.098_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbrc.2016.07.098_bib20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","article-title":"Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the therapeutics and technology assessment subcommittee of the American academy of neurology","volume":"76","author":"Cortese","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2016.07.098_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00234-007-0216-2","article-title":"Idiopathic inflammatory-demyelinating diseases of the central nervous system","volume":"49","author":"Canellas","year":"2007","journal-title":"Neuroradiology"},{"key":"10.1016\/j.bbrc.2016.07.098_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2016.07.098_bib23","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","article-title":"A\u00a0consensus protocol for the standardization of cerebrospinal fluid collection and biobanking","volume":"73","author":"Teunissen","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2016.07.098_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.nbd.2011.12.056","article-title":"Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion","volume":"46","author":"Kim","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbrc.2016.07.098_bib25","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.neuroscience.2012.08.041","article-title":"Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica","volume":"226","author":"Wang","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbrc.2016.07.098_bib26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.chembiol.2007.03.007","article-title":"Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities","volume":"14","author":"Mollica","year":"2007","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bbrc.2016.07.098_bib27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult. Scler. (Houndmills, Basingstoke, Engl.)"},{"key":"10.1016\/j.bbrc.2016.07.098_bib28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.bbrc.2016.07.098_bib29","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbrc.2016.07.098_bib30","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol"},{"key":"10.1016\/j.bbrc.2016.07.098_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","article-title":"Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies","volume":"89","author":"Wingerchuk","year":"2014","journal-title":"Mayo Clin. Proc."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X16312207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X16312207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T02:37:02Z","timestamp":1617331022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X16312207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0006291X16312207"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2016.07.098","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycyrrhizic acid prevents astrocyte death by neuromyelitis optica-specific IgG via inhibition of C1q binding","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2016.07.098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}